Scholars Central

Case reportPublished 2018

Leukocytoclastic Vasculitis Associated with Exemestane/Everolimus Therapy in a Previously Irradiated Skin: Case Report

Authors: Cvetka Grasi Kuhar, Klara Gersakandivojin Stevanovi, Barbara Gazi

British Journal of Research

Volume 5 · Issue 1

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Leukocytoclastic vasculitis may be secondary to medications, underlying infection, collagen-vascular disorders, or malignancy. We report the second case of leukocytoclastic vasculitis related to exemestane/ everolimus therapy in breast cancer and present our review of literature. Case presentation: A 68-year-old Caucasian woman, treated with exemestane and everolimus for metastatic breast cancer presented with skin necrosis and allodynia in the right mammary region. A biopsy disclosed leukocytoclastic vasculitis. The patient received radiation therapy to the right breast due to exulcerated breast cancer (20 × 2.5 Gy, total dose 50 Gy) two and a half years ago. Skin necrosis appeared after five days of treatment with everolimus and 22 days of exemestane. The treatment with exemestane was continued, but everolimus was discontinued. Allodynia disappeared in two weeks after everolimus discontinuation. The skin healed very slowly and an eschar persisted for several months. The prompt resolution of allodynia, evident healing of skin necrosis after everolimus discontinuation, and high score in the Naranjo Adverse Drug Reaction Probability Scale strongly suggest the causative role of everolimus in leukocytoclastic vasculitis. A review of literature revealed only one case of leukocytoclastic vasculitis caused by everolimus and one case of radiation recall dermatitis caused by exemestane/ everolimus. Even though it is a serious adverse effect, it is usually reversible by drug discontinuation and symptomatic treatment only. Conclusion: Everolimus-related skin recall presented as leukocytoclastic vasculitis is a very rare adverse drug reaction.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in British Journal of Research.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalBritish Journal of Research
  • SubjectDermatology
  • SubjectOncology & Cancer
  • SubjectRadiology & Imaging
  • BylineArticles whose byline prints “Cvetka Grasi Kuhar”
  • BylineArticles whose byline prints “Klara Gersakandivojin Stevanovi”
  • BylineArticles whose byline prints “Barbara Gazi”